151. 0208: Impact of fondaparinux versus enoxaparin on in-hospital bleeding and one-year death in non-ST-segment elevation myocardial infarction. FAST-MI 2010 registry
- Author
-
Simon Tabassome, P. Richard, Etienne Puymirat, Gerald Roul, Ennezat Pierre-Vladimir, Nicolas Danchin, Jean-Phillipe Collet, Pierre Coste, Eric Bonnefoy-Cudraz, and Francois Schiele
- Subjects
medicine.medical_specialty ,business.industry ,medicine.drug_class ,Hazard ratio ,Anticoagulant ,Low molecular weight heparin ,medicine.disease ,Fondaparinux ,Surgery ,Internal medicine ,Propensity score matching ,Cohort ,medicine ,ST segment ,Myocardial infarction ,business ,Cardiology and Cardiovascular Medicine ,medicine.drug - Abstract
Aims Fondaparinux is an alternative to low molecular weight heparin (LMWH) for non-ST-elevation myocardial infarction (NSTEMI) with levels of recommendation that differ according to guidelines. The aim of this study was to assess one-year survival in real world practice in NSTEMI patients participating in the French Registry of ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2010 according to the use of fondaparinux, in comparison with patients receiving enoxaparin. Methods and Results FAST-MI 2010 is a nationwide French registry that included 4,169 patients with acute myocardial infarction (AMI) at the end of 2010 in 213 centres (76% of active centres in France). Of those, 1,734 had NSTEMI, of whom 240 received fondaparinux and 1,027 enoxaparin. Patients receiving enoxaparin vs. fondaparinux were similar for many characteristics; especially with a similar GRACE (Global Registry of Acute Coronary Events) score (133±36 vs. 134±38). Invasive strategy was used in 69% in both groups. In-hospital bleeding was similar with both anticoagulant strategies and one-year survival was 94.6% vs. 91.7% respectively. Using fully adjusted Cox multivariate analysis, the use of fondaparinux was not associated with a reduced risk of death (hazard ratio [HR]: 1.35; 95% confidence interval [CI]: 0.70-2.51). After propensity score matching (207 patients per group), one-year survival was similar with both strategies. Conclusions In this real-world cohort of NSTEMI patients, most of whom were managed invasively, there was no evidence that fondaparinux was superior to enoxaparin as regards bleeding events or one-year mortality. (FAST-MI 2010; NCT01237418)
- Published
- 2015
- Full Text
- View/download PDF